BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 27825109)

  • 21. [Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].
    Han Y; Xu JM; Duan HQ; Zhang Y; Liu XQ; Zhang JS
    Chin J Cancer; 2010 Jan; 29(1):69-75. PubMed ID: 20038315
    [TBL] [Abstract][Full Text] [Related]  

  • 22. NSCLC and HER2: between lights and shadows.
    Ricciardi GR; Russo A; Franchina T; Ferraro G; Zanghì M; Picone A; Scimone A; Adamo V
    J Thorac Oncol; 2014 Dec; 9(12):1750-62. PubMed ID: 25247338
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Activity of Pan-HER Inhibitors Against HER2-Mutant Lung Adenocarcinoma.
    Oh IJ; Hur JY; Park CK; Kim YC; Kim SJ; Lee MK; Kim HJ; Lee KY; Lee JC; Choi CM
    Clin Lung Cancer; 2018 Sep; 19(5):e775-e781. PubMed ID: 30149884
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune microenvironment features and efficacy of PD-1/PD-L1 blockade in non-small cell lung cancer patients with EGFR or HER2 exon 20 insertions.
    Chen K; Pan G; Cheng G; Zhang F; Xu Y; Huang Z; Fan Y
    Thorac Cancer; 2021 Jan; 12(2):218-226. PubMed ID: 33210451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Driver gene alterations profiling of Chinese non-small cell lung cancer and the effects of co-occurring alterations on immunotherapy.
    Sun S; Du W; Sun Q; Zhao X; Qin B; Shi D; Wan C; Wu Z
    Cancer Med; 2021 Oct; 10(20):7360-7372. PubMed ID: 34599863
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of EML4-ALK fusion gene and association with EGFR and KRAS gene mutations in 208 Chinese patients with non-small cell lung cancer.
    Li Y; Li Y; Yang T; Wei S; Wang J; Wang M; Wang Y; Zhou Q; Liu H; Chen J
    PLoS One; 2013; 8(1):e52093. PubMed ID: 23341890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.
    Song Z; Yu X; Zhang Y
    Lung Cancer; 2016 Nov; 101():16-21. PubMed ID: 27794403
    [TBL] [Abstract][Full Text] [Related]  

  • 29. p95HER2 truncated form in resected non-small cell lung cancer.
    Cappuzzo F; Cho YG; Sacconi A; Alì G; Siclari O; Incarbone M; Destro A; Terracciano L; Fontanini G; Marchetti A; Roncalli M; Varella-Garcia M
    J Thorac Oncol; 2012 Mar; 7(3):520-7. PubMed ID: 22307009
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.
    Gow CH; Hsieh MS; Wu SG; Shih JY
    Lung Cancer; 2017 Jan; 103():82-89. PubMed ID: 28024701
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation.
    Ding X; Zhang Z; Jiang T; Li X; Zhao C; Su B; Zhou C
    Cancer Med; 2017 Mar; 6(3):555-562. PubMed ID: 28135039
    [TBL] [Abstract][Full Text] [Related]  

  • 32. HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
    Ou SI; Schrock AB; Bocharov EV; Klempner SJ; Haddad CK; Steinecker G; Johnson M; Gitlitz BJ; Chung J; Campregher PV; Ross JS; Stephens PJ; Miller VA; Suh JH; Ali SM; Velcheti V
    J Thorac Oncol; 2017 Mar; 12(3):446-457. PubMed ID: 27903463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.
    Cai D; Hu C; Li L; Deng S; Yang J; Han-Zhang H; Li M
    Cancer Med; 2020 Jan; 9(1):84-93. PubMed ID: 31709742
    [TBL] [Abstract][Full Text] [Related]  

  • 34. K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic Pathways.
    Scheffler M; Ihle MA; Hein R; Merkelbach-Bruse S; Scheel AH; Siemanowski J; Brägelmann J; Kron A; Abedpour N; Ueckeroth F; Schüller M; Koleczko S; Michels S; Fassunke J; Pasternack H; Heydt C; Serke M; Fischer R; Schulte W; Gerigk U; Nogova L; Ko YD; Abdulla DSY; Riedel R; Kambartel KO; Lorenz J; Sauerland I; Randerath W; Kaminsky B; Hagmeyer L; Grohé C; Eisert A; Frank R; Gogl L; Schaepers C; Holzem A; Hellmich M; Thomas RK; Peifer M; Sos ML; Büttner R; Wolf J
    J Thorac Oncol; 2019 Apr; 14(4):606-616. PubMed ID: 30605727
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Correlation of clinicopathologic features and driver gene mutation in non-small cell lung cancer].
    Chen LF; Chen XY; Yu XB
    Zhonghua Bing Li Xue Za Zhi; 2016 Apr; 45(4):221-5. PubMed ID: 27033383
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic value analysis of mutational and clinicopathological factors in non-small cell lung cancer.
    Li C; Hao L; Li Y; Wang S; Chen H; Zhang L; Ke B; Yin Y; Suo H; Sun B; Zhang B; Wang C
    PLoS One; 2014; 9(9):e107276. PubMed ID: 25198510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases.
    Luo D; Ye X; Hu Z; Peng K; Song Y; Yin X; Zhu G; Ji Q; Peng Y
    Tumour Biol; 2014 Mar; 35(3):2437-44. PubMed ID: 24197981
    [TBL] [Abstract][Full Text] [Related]  

  • 38. EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
    Xu JM; Han Y; Duan HQ; Gao EM; Zhang Y; Liu XQ; Zhang JS; Toschi L; Galetta D; Azzariti A; Paradiso A
    J Cancer Res Clin Oncol; 2009 Jun; 135(6):771-82. PubMed ID: 19020901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
    Fang W; Zhao S; Liang Y; Yang Y; Yang L; Dong X; Zhang L; Tang Y; Wang S; Yang Y; Ma X; Wang M; Wang W; Zhao S; Wang K; Gao S; Zhang L
    Oncologist; 2020 Mar; 25(3):e545-e554. PubMed ID: 32162827
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer.
    Jao K; Tomasini P; Kamel-Reid S; Korpanty GJ; Mascaux C; Sakashita S; Labbé C; Leighl NB; Liu G; Feld R; Bradbury PA; Hwang DM; Pintilie M; Tsao MS; Shepherd FA
    Lung Cancer; 2018 Sep; 123():22-29. PubMed ID: 30089591
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.